Yüklüyor......
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
Progress in the development of new therapies for cystic fibrosis (CF) has benefitted from therapeutically responsive biomarkers to streamline drug development. Paradoxically, these response biomarkers have proven to be essential even in the presence of data demonstrating a lack of correlation with c...
Kaydedildi:
| Yayımlandı: | Trends Mol Med |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708517/ https://ncbi.nlm.nih.gov/pubmed/32868171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmed.2020.08.002 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|